51
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          Research over the past decade has suggested important roles for pseudogenes in physiology and disease. In vitro experiments demonstrated that pseudogenes contribute to cell transformation through several mechanisms. However, in vivo evidence for a causal role of pseudogenes in cancer development is lacking. Here we report that mice engineered to overexpress either the full-length murine B-Raf pseudogene, Braf-rs1, or its pseudo “CDS” or “3’UTR” develop an aggressive malignancy resembling human diffuse large B-cell lymphoma. We show that Braf-rs1 and its human ortholog, BRAFP1, elicit their oncogenic activity, at least in part, as competitive endogenous RNAs (ceRNAs) that elevate BRAF expression and MAPK activation in vitro and in vivo. Notably, we find that transcriptional or genomic aberrations of BRAFP1 occur frequently in multiple human cancers including B-cell lymphomas. Our engineered mouse models demonstrate the oncogenic potential of pseudogenes, and indicate that ceRNA-mediated microRNA sequestration may contribute to the development of cancer.

          Related collections

          Author and article information

          Journal
          0413066
          2830
          Cell
          Cell
          Cell
          0092-8674
          1097-4172
          2 December 2019
          02 April 2015
          09 April 2015
          19 December 2019
          : 161
          : 2
          : 319-332
          Affiliations
          [1 ]Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
          [2 ]Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
          [3 ]Experimental Cancer Genetics, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, CB10 1HH, UK
          [4 ]Department of Physiology and Biophysics, Institute for Computational Biomedicine, Weill Cornell Medical College, New York, NY 10021
          [5 ]Meyer Cancer Center, Weill Cornell Medical College, New York, NY 10021
          [6 ]Department of Pathology, Children’s Hospital and Harvard Medical School, Boston, MA 02115, USA
          [7 ]Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02115, USA
          [8 ]Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
          Author notes

          Author Contribution

          F.A.K. and P.P.P conceived and designed the study. F.A.K., M.R., A.R., Y.T., D.W., N.S. and A.B., performed experiments, and F.A.K., M.R. and P.P.P analyzed most data. C.N., J.F. and F.L. carried out immunohistochemistry. U.A. performed miRNA predictions. R.C. and S.J.R. evaluated histopathology of tumors and advised on immunohistochemical validation. M.S., T.M.K., M.D.C.VH. and D.J.A. performed RNAseq analysis. B.C. and M.A.S. provided human samples and cell lines. A.V. and O.E. analyzed BRAFP1 expression in human RNAseq data. F.A.K. and P.P.P. wrote the manuscript with contributions from all authors.

          Correspondence should be addressed to Pier Paolo Pandolfi ppandolf@ 123456bidmc.harvard.edu
          Article
          PMC6922011 PMC6922011 6922011 nihpa677596
          10.1016/j.cell.2015.02.043
          6922011
          25843629
          556d8d0e-38c2-4c2b-8810-79529d1fafe5
          History
          Categories
          Article

          Comments

          Comment on this article